Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
S. Z. Wu, D. L. Roden, C. Wang, H. Holliday, K. Harvey, A. S. Cazet, K. J. Murphy, B. Pereira, G. Al-Eryani, N. Bartonicek, R. Hou, J. R. Torpy, S. Junankar, C.-L. Chan, E. Lam, , A. Swarbrick
This study identifies diverse stromal subsets in TNBC using single-cell RNA-seq and links them to immune evasion mechanisms and therapeutic targets.
bioRxiv · Jun 4, 2020Cancer Biology
S. Z. Wu, D. L. Roden, G. Al-Eryani, N. Bartonicek, K. Harvey, A. S. Cazet, C.-L. Chan, S. Junankar, M. N. Hui, E. Millar, J. Beretov, L. Horvath, A. M. Joshua, P. Stricker, J. S. Wilmott, , A. Swarbrick
This study shows that cryopreservation of human cancers preserves tumour heterogeneity for single-cell multi-omics analysis, with comparable results to fresh tissue.
bioRxiv · Jun 4, 2020Cancer Biology
W. S. Teo, H. Holliday, N. Karthikeyan, A. S. Cazet, D. L. Roden, K. Harvey, C. V. Konrad, R. Murali, B. A. Varghese, A. P. T., C.-L. Chan, A. McFarland, S. Junankar, S. Ye, J. Yang, , R. Nair
This study shows that Id proteins promote a cancer stem cell phenotype in triple negative breast cancer by negatively regulating Robo1, leading to Myc activation.
bioRxiv · Mar 11, 2020 · PreprintCancer Biology
R. Murali, B. A. Varghese, N. Karthikeyan, A. P. T, W. S. Teo, A. McFarland, D. L. Roden, H. Holliday, C. Konrad, A. S. Cazet, E. Dodson, J. T. George, H. Levine, M. K. Jolly, A. Swarbrick, R. Nair
This paper investigates how Id1 and Id3 maintain chemoresistant CSCs in TNBC by targeting Kif11 and Aurka, and explores combination therapy to enhance tumor debulking.
bioRxiv · Sep 11, 2019 · PreprintCancer Biology
A. S. Cazet, M. N. Hui, B. L. Elsworth, S. Z. Wu, D. Roden, C.-L. Chan, J. N. Skhinas, R. Collot, J. Yang, K. Harvey, M. Z. Johan, C. Cooper, R. Nair, D. Herrmann, A. McFarland, , A. Swarbrick
This study identifies Hedgehog signaling to cancer-associated fibroblasts as a driver of cancer stem cell plasticity and chemoresistance in TNBC, showing that targeting this pathway with smoothened inhibitors improves survival in preclinical models and clinical trials.
bioRxiv · Nov 8, 2017Cancer Biology